<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154492">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01088737</url>
  </required_header>
  <id_info>
    <org_study_id>Trial Photoderm Graz 2010-1</org_study_id>
    <nct_id>NCT01088737</nct_id>
  </id_info>
  <brief_title>Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna</brief_title>
  <official_title>An Open Monocentric Pilot Study to Investigate the Potential of Imiquimod 5% Cream to Detect Residual and to Prevent Recurrence of Lentigo Maligna After Surgical Excision</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, longitudinal, uncontrolled study with follow-up for 5 years.Patients
      having undergone surgical excision of lentigo maligna (LM) or lentigo maligna melanoma (LMM)
      will be invited to this study. Eligible patients will start treatment with imiquimod 6 weeks
      after the excision, the treatment will last for up to 12 weeks. Inflammatory reactions and
      the occurrence of residual lesions will be documented. The healing effect will be determined
      (initial clearance rate) 20 weeks after start of treatment with imiquimod. All patients who
      were enrolled (=exposed to imiquimod in this study) will be followed up for 5 years or until
      recurrence of the LM or LMM
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Imiquimod (Aldara) 5% cream will be applied starting 6 weeks post-surgery to an area within
      5 cm of treatment margins to each side of the original scar of the LM or LMM excision. Time
      period between removal of stitches and first administration of imiquimod should be 4 weeks,
      correspondent to approximate 6 weeks post surgery. Imiquimod cream is applied once daily.
      Each patient will begin with the application 3x/week. After two weeks of treatment the
      inflammation response to imiquimod will be assessed. If no or only minor inflammation is
      detectable in the treatment area, the dosing schedule will be increased to 5x/week. After
      four weeks of treatment the inflammation response will be assessed again. If still no or
      only minor inflammation is detectable, application will be extended to daily use. An
      interruption of the treatment with imiquimod cream is considered if severe local
      inflammatory reaction occurs, severe systemic reactions are apparent or if super-infection
      is observed at the treatment area. The primary objective of the study is to investigate the
      potential of imiquimod 5% cream to eliminate possible subclinical lesions of LM that resides
      after surgical excision by determining the long-term recurrence rates. Secondary objectives
      of the study describe the incidence of subclinical residual lesions and local skin
      reactions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Elimination of possible subclinical lesions of LM that resides after surgical excision by determining the long-term recurrence rates.</measure>
    <time_frame>60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of subclinical residual lesions and local skin reactions.</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Lentigo Maligna</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod</intervention_name>
    <description>Imiquimod 5% cream is applied once daily. Each patient will begin with the application 3x/week. After two weeks of treatment the inflammation response to imiquimod will be assessed. If no or only minor inflammation is detectable in the treatment area, the dosing schedule will be increased to 5x/week. After four weeks of treatment the inflammation response will be assessed again. If still no or only minor inflammation is detectable, application will be extended to daily use.</description>
    <other_name>Aldara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Having undergone surgical excision of LM or LMM

          -  Positive histological finding of LM or LMM (positive histology of primary excision)

        Exclusion Criteria:

          -  History of allergic reaction to imiquimod or its excipients.

          -  Pregnancy, breast-feeding or planned pregnancy during the study and women of
             child-bearing potential not using adequate contraception. Women of child bearing
             potential not using a highly effective method of birth control defined as those which
             result in a low failure rate (i.e. &lt;1% per year) when used consistently and correctly
             such as implants, injectables, combined oral contraceptives, hormonal IUDs, tubal
             ligation or vasectomised partner

          -  History of malignant melanoma having metastasised or where metastasis could be
             expected

          -  Other malignant tumours in the study treatment area (exception actinic keratosis
             (AK))

          -  Lack of ability or willingness to give informed consent

          -  Lack of willingness to have personal study related data collected, archived or
             transmitted according to protocol

          -  Anticipated non-availability for study visits/procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Wolf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz, Austria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Wolf, MD</last_name>
    <phone>+43 316 385</phone>
    <phone_ext>80315</phone_ext>
    <email>peter.wolf@medunigraz.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ingrid Wolf, MD+</last_name>
    <phone>+43 316 385</phone>
    <phone_ext>13254</phone_ext>
    <email>ingrid.wolf@medunigraz.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Graz, Dept. Dermatology</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Wolf, MD</last_name>
      <phone>+43 316 385</phone>
      <phone_ext>13254</phone_ext>
      <email>peter.wolf@medunigraz.at</email>
    </contact>
    <contact_backup>
      <last_name>Ingrid Wolf, MD</last_name>
      <phone>+43 316 385</phone>
      <phone_ext>13254</phone_ext>
      <email>ingrid.wolf@medunigraz.at</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ingrid Wolf, MD</last_name>
      <phone>+43 316 385</phone>
      <phone_ext>13254</phone_ext>
      <email>ingrid.wolf@medunigraz.at</email>
    </contact>
    <contact_backup>
      <last_name>Peter Wolf, MD+</last_name>
      <phone>+43 316 385</phone>
      <phone_ext>12371</phone_ext>
      <email>peter.wolf@medunigraz.at</email>
    </contact_backup>
    <investigator>
      <last_name>Ingrid Wolf, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Verena Ahlgriem-Siess, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Regina Fink-Puches, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rainer Hofmann-Wellenhof, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erika Richtig, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Helmut Schaider, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra Gruber-Wackernagel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Wolf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 23, 2016</lastchanged_date>
  <firstreceived_date>March 16, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Graz</investigator_affiliation>
    <investigator_full_name>Peter Wolf, MD</investigator_full_name>
    <investigator_title>Professor of Bioimmunotherapy</investigator_title>
  </responsible_party>
  <keyword>Lentigo maligna</keyword>
  <keyword>melanoma</keyword>
  <keyword>imiquimod</keyword>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Lentigo</mesh_term>
    <mesh_term>Hutchinson's Melanotic Freckle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
